Daniel Okafor

Tracker/Cross-border deals

Drugs discovered in China are reshaping dealmaking. Track the licensing agreements here.

Western drugmakers have signed 37 licensing deals for China-originated medicines this year, already more than in all of 2025.

Updated Sept. 29, 2026·Deals

News roundup

Halvern and Palisade part ways; Sundari names a new research chief

Also this week: a manufacturing expansion in Ireland and a $180 million financing for a company developing drugs in orbit.

Sept. 28, 2026·Biotech

Sundari and Corvane widen alliance to find long-acting antibodies

The expanded agreement carries a $600 million upfront payment and adds four targets in inflammatory disease.

Sept. 27, 2026·Deals

Tracker/IPO window

Biotech IPOs are the sector's lifeblood. Here is how this year's class is performing.

Eleven drug developers have listed in the U.S. this year. Seven are trading above their offering price.

Updated Sept. 25, 2026·Biotech

Deep Dive

Biotech acquisitions are accelerating. Follow the deals as they happen.

Buyers have announced 19 acquisitions worth $1 billion or more this year, with rare disease companies the most frequent targets.

Updated Sept. 22, 2026·Deals

Obesity drugs

Arden & Pryce to pay up to $2.4 billion for a once-weekly obesity pill

The agreement gives the drugmaker a challenger to market-leading injections as it tries to reassure investors about growth after 2030.

Sept. 17, 2026·Deals

Deep Dive/Emerging biotech

Biotech startups run on venture capital. Track this year's funding rounds.

Six companies raised more than $700 million between them last week, though two rounds accounted for most of the total.

Updated Sept. 14, 2026·Biotech